Crinetics Pharmaceuticals And The Ferring Research Institute, Inc. Sign Collaboration Agreement
Published: Jan 14, 2010
SAN DIEGO, CA. — Crinetics Pharmaceuticals today announced entering into a collaboration agreement with Ferring Research Institute (FRI), the peptide research center of excellence for Ferring Pharmaceuticals, a privately held, research-driven, global, specialty biopharmaceutical company. Crinetics will apply components of its G Protein-Coupled Receptor (GPCR) Dynamics assay platform to a Ferring proprietary drug discovery target. Financial terms of the agreement were not disclosed. “We are pleased to be working with Crinetics to explore new pharmacologic tools to enhance our peptide drug discovery efforts directed at GPCRs,” said Pierre Rivière, Ph.D., Managing Director & Vice President Research at FRI. "We are excited to collaborate with a world leader in discovery and development of peptide drugs directed at GPCRs. Our collaboration benefits both Ferring and Crinetics by improving the tools available for GPCR drug discovery while at the same time allowing both companies to advance their independent drug discovery efforts," said R. Scott Struthers, Ph.D., Founder and Chief Scientific Officer of Crinetics Pharmaceuticals. “Ferring is an important anchor for the San Diego biotechnology community and we greatly appreciate their support at this early stage in Crinetics’ development,” he added. Crinetics Pharmaceuticals Inc. (www.crinetics.com) is a startup company located in the heart of the San Diego biotechnology community. The company is focused on developing and applying next generation pharmacology tools within an aggressive drughunter based culture. The company’s GPCR Dynamics Platform enables lead optimization based on fundamental pharmacologic properties typically only available for advanced clinical compounds. Our internal drug discovery pipeline is focused on endocrine GPCRs that provide biochemical proof-of-concept in early clinical studies and offer significant therapeutic advances for large markets. Ferring is a Swiss-headquartered, research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of urology, endocrinology, gastroenterology, gynaecology, and fertility. In recent years Ferring has expanded beyond its traditional European base and now has offices in over 40 countries. To learn more about Ferring or our products please visit www.ferring.com.